Cellectar Reports Case Study of Eight-Year Response to Iopofosine I 131
The company reported a case study describing a complete response lasting more than eight years in a heavily pretreated DLBCL patient treated with iopofosine I 131.
Related stories
ICE Partners With Trade[XYZ] to Bring Hyperliquid Perpetual Futures to U.S.
Intercontinental Exchange said it is partnering with the creator behind popular perpetual futures on Hyperliquid to bring the contracts to the U.S.
L impact | EQUITY | Oct 29, 2026, 03:37 PM UTC
Nasdaq Trading Halt Continues
Nasdaq trading remains halted; the reason is not available.
M impact | EQUITY | Oct 29, 2026, 03:34 PM UTC
Nasdaq halts trading for volatility pause
Nasdaq trading was paused for volatility at 11:34 a.m.
M impact | EQUITY | Oct 29, 2026, 03:34 PM UTC
IIFL Capital launches Sagility block deal worth up to $249.6 million
The offer price could be around Rs 42.45 per share, at a discount to Sagility's October 29 close. Sagility B.V. is expected to be the seller, sources told Moneycontrol.
M impact | EQUITY | Oct 29, 2026, 03:31 PM UTC
DoorDash to Acquire Instacart in $17 Billion Deal
DoorDash has agreed to acquire Maplebear, Instacart’s parent, in a $17 billion deal. The headline also says quarterly results topped views.
H impact | EQUITY | Oct 29, 2026, 03:31 PM UTC
Summi Group Delays Publication of FY26 Annual Results
M impact | EQUITY | Oct 29, 2026, 03:31 PM UTC